Australia's Nexalis Therapeutics gains most in over 6 months on trial approval

Nexalis Therapeutics

17/04/2026 07:01

** Shares of Australia's Nexalis Therapeutics NX1.AX rise as much as 21.1% to A$0.023, their biggest intraday pct gain since October 9, 2025

** Stock touches its highest level since March 26

** The clinical stage drug developer receives an approval from Australian health regulator Safety Review Committee (SRC) for a second trial for dosing of acute pain reliever, IRX-616a

** Stock up 27.8% so far this week, set for its best week in over a year, if gains hold

** Despite moves, stock down 4.2% YTD

 (Reporting by Aamir Sheik Khalid in Bengaluru)

 ((Aamir.SheikKhalid@thomsonreuters.com))